117 related articles for article (PubMed ID: 23694959)
1. [Anticancer drug adherence].
Despas F; Roche H; Laurent G
Bull Cancer; 2013 May; 100(5):473-84. PubMed ID: 23694959
[TBL] [Abstract][Full Text] [Related]
2. Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia.
Al-Barrak J; Cheung WY
Support Care Cancer; 2013 Aug; 21(8):2351-7. PubMed ID: 23708821
[TBL] [Abstract][Full Text] [Related]
3. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
Breccia M; Luciano L; Latagliata R; Castagnetti F; Ferrero D; Cavazzini F; Trawinska MM; Annunziata M; Stagno F; Tiribelli M; Binotto G; Crisà E; Musto P; Gozzini A; Cavalli L; Montefusco E; Iurlo A; Russo S; Cedrone M; Rossi AR; Pregno P; Endri M; Spadea A; Molica M; Giglio G; Celesti F; Sorà F; Storti S; D'Addosio A; Cambrin GR; Isidori A; Sica S; Abruzzese E; Speccha G; Rosti G; Alimena G
Leuk Res; 2014 Oct; 38(10):1173-6. PubMed ID: 25047978
[TBL] [Abstract][Full Text] [Related]
4. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
Eliasson L; Clifford S; Barber N; Marin D
Leuk Res; 2011 May; 35(5):626-30. PubMed ID: 21095002
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate--a new oral targeted therapy.
Savage DG; Antman KH
N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
[No Abstract] [Full Text] [Related]
6. Imatinib mesylate: A designer drug.
Panigrahi I; Naithani R
J Assoc Physicians India; 2006 Mar; 54():203-6. PubMed ID: 16800347
[TBL] [Abstract][Full Text] [Related]
7. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
Daouphars M; Ouvry M; Lenain P; Rouvet J; Jardin F; Bubenheim M; Varin R
Pharmacotherapy; 2013 Feb; 33(2):152-6. PubMed ID: 23359430
[TBL] [Abstract][Full Text] [Related]
8. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
von Bubnoff N; Peschel C; Duyster J
Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
[TBL] [Abstract][Full Text] [Related]
9. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Teng JF; Mabasa VH; Ensom MH
Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
[TBL] [Abstract][Full Text] [Related]
10. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors.
Blay JY; Rutkowski P
Cancer Treat Rev; 2014 Mar; 40(2):242-7. PubMed ID: 23931926
[TBL] [Abstract][Full Text] [Related]
11. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Hochhaus A
Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
[No Abstract] [Full Text] [Related]
12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
13. Adherence to targeted oral anticancer medications.
Geynisman DM; Wickersham KE
Discov Med; 2013 Apr; 15(83):231-41. PubMed ID: 23636140
[TBL] [Abstract][Full Text] [Related]
14. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
15. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
Pfeifer H; Wassmann B; Bethge W; Dengler J; Bornhäuser M; Stadler M; Beelen D; Vucinic V; Burmeister T; Stelljes M; Faul C; Dreger P; Kiani A; Schäfer-Eckart K; Schwerdtfeger R; Lange E; Kubuschok B; Horst HA; Gramatzki M; Brück P; Serve H; Hoelzer D; Gökbuget N; Ottmann OG;
Leukemia; 2013 Jun; 27(6):1254-62. PubMed ID: 23212150
[TBL] [Abstract][Full Text] [Related]
17. The safety profile of imatinib in CML and GIST: long-term considerations.
Thanopoulou E; Judson I
Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
[TBL] [Abstract][Full Text] [Related]
18. [Imatinib--a new perspective in the treatment of tumors].
Klener P; Klamová H
Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
[TBL] [Abstract][Full Text] [Related]
19. Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission.
Cherrier-De Wilde S; Rack K; Vannuffel P; Delannoy A; Hagemeijer A
Leukemia; 2003 Oct; 17(10):2046-8. PubMed ID: 14513056
[No Abstract] [Full Text] [Related]
20. Cancer of cervical stump diagnosed in a woman with chronic myelogenous leukaemia.
Dogan NU; Gungor T; Sahin I; Karsli F
J Obstet Gynaecol; 2013 May; 33(4):428-9. PubMed ID: 23654340
[No Abstract] [Full Text] [Related]
[Next] [New Search]